RPL22L1 fosters malignant features of cervical cancer via the modulation of DUSP6-ERK axis
RPL22L1 promotes malignant biological behavior of cervical cancer cells by competitively binding with DUSP6, thereby activating the ERK pathway. The combined use of Sorafenib and an ERK inhibitor is a potentially effective molecular targeted therapy for RPL22L1-high cervical cancer.
Authors
- Hongxue Meng (ORCID: https://orcid.org/0000-0002-1831-2737)
- Yu Mu
- Shangwei Ning (ORCID: https://orcid.org/0000-0003-4079-8945)
- Shan Xiao (ORCID: https://orcid.org/0000-0002-3667-7262)
- Chong Zhou
- Nan Wu (ORCID: https://orcid.org/0000-0002-7401-4136)
- Guohua Ji
- Yan Xu (ORCID: https://orcid.org/0000-0002-2832-2664)
- Yunzhen Zhou
- Donglin Sun (ORCID: https://orcid.org/0000-0001-5142-7272)
- Dongmei Zhang (ORCID: https://orcid.org/0000-0001-6180-0253)
- Yan Jin (ORCID: https://orcid.org/0000-0001-6282-7095)
- Ping Jiang (ORCID: https://orcid.org/0009-0003-9415-5715)
- Sheng Xiao
- Meiqi Zhao (ORCID: https://orcid.org/0009-0004-5077-4909)
- Xiaobo Cui (ORCID: https://orcid.org/0000-0002-4508-4223)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Harbin Medical University (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1186/s12967-025-06249-0
- Citations
- 2
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Department of Education, Heilongjiang Province
- Natural Science Foundation of Heilongjiang Province
- Postdoctoral Research Foundation of China